Today: 9 June 2026
Browse Category

NASDAQ:MMYT 9 January 2026 - 6 March 2026

MakeMyTrip to Buy Flamingo Transworld Stake as India Holiday Package Travel Grows

MakeMyTrip to Buy Flamingo Transworld Stake as India Holiday Package Travel Grows

MakeMyTrip said Thursday it will acquire a majority stake in Flamingo Transworld, a regional tour operator, with no price disclosed and deal closing pending. Flamingo operates mainly in Gujarat, Maharashtra, Rajasthan, and Madhya Pradesh through 51 offices. MakeMyTrip’s hotels and packages revenue rose 9.7% last quarter to $161.4 million, while air ticketing fell. Net profit for the quarter dropped to $7.3 million from $27.1 million.
6 March 2026
·
Booking (BKNG) stock price slips as March split and dividend dates tighten the calendar

Booking (BKNG) stock price slips as March split and dividend dates tighten the calendar

Booking Holdings shares fell 0.26% to $4,239.35 Friday as the company announced a 25-for-1 stock split, with new shares distributed after April 2. The board declared a $10.50 per share dividend payable March 31. Executives reported lower average daily rates and shorter stays in the U.S. Travel stocks broadly declined, with Expedia and TripAdvisor also closing lower.
28 February 2026
····
Booking Holdings (BKNG) stock slips as Booking.com expands Navan tie-up ahead of Feb. 18 results

Booking Holdings (BKNG) stock slips as Booking.com expands Navan tie-up ahead of Feb. 18 results

Booking Holdings shares slipped 0.25% to $5,150.90 Thursday, bucking gains in broader U.S. indexes and sector peers like Expedia. Trading volume reached about 220,000 shares. The company set February 18 for its fourth-quarter and full-year results release. Navan announced an expanded API integration with Booking.com to offer more lodging options for business travelers.
23 January 2026
······
MakeMyTrip stock slides 4.5% in U.S. trade as investors turn to Jan. 22 earnings

MakeMyTrip stock slides 4.5% in U.S. trade as investors turn to Jan. 22 earnings

MakeMyTrip shares fell 4.5% to $78.78 in Friday afternoon trading, underperforming U.S.-listed travel peers. The stock hit a session high of $83.42 before sliding, with no new company updates ahead of its expected Jan. 22 earnings. Trading volume reached about 577,000 shares by mid-session. The drop puts MakeMyTrip near its lowest levels since early January.
9 January 2026
··

Stock Market Today

  • NSE Allocates 10% of Annual CSR Fund to Social Stock Exchange
    June 9, 2026, 10:16 AM EDT. The National Stock Exchange (NSE) will deploy 10% of its annual Corporate Social Responsibility (CSR) corpus through the Social Stock Exchange, signaling trust in this market-based platform designed to connect social enterprises with investors. This move aims to enhance transparency and impact investing by leveraging the exchange's resources to support social causes.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Go toTop